[CNCE] Concert Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 10.1 Change: 0.56 (5.87%)
Ext. hours: Change: 0 (0%)

chart CNCE

Refresh chart

Description: Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation, and cancer. The company?s clinical-stage product candidates include CTP-354, which in Phase I clinical trial for spasticity associated with multiple sclerosis and spinal cord injury; CTP-499 that is in Phase II clinical trial for diabetic kidney disease; and AVP-786 for neurologic and psychiatric disorders. Its preclinical compounds comprise CTP-730 for inflammatory diseases; JZP-386, a deuterated analog of sodium oxybate for narcolepsy; and C-10068, an oral deuterium-substituted analog of dextroethorphan, which is used for the treatment of pain and seizure-generating diseases and injuries, such as epilepsy, ischemic stroke, and traumatic brain injury. The company has collaborations with Avanir Pharmaceuticals, Inc., Celgene Corporation, Celgene International Sàrl, and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. w

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.75% Sales Growth - Q/Q-0.31% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.52% ROE-36.1% ROI
Current Ratio7.95 Quick Ratio Long Term Debt/Equity Debt Ratio0.16
Gross Margin Operating Margin-398.48% Net Profit Margin-408.16% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities45.18 M Cash From Investing Activities16.27 M Cash From Operating Activities-11.04 M Gross Profit
Net Profit-9 M Operating Profit-8.87 M Total Assets118.36 M Total Current Assets115.64 M
Total Current Liabilities14.55 M Total Debt5.04 M Total Liabilities24.87 M Total Revenue1.31 M
Technical Data
High 52 week29.05 Low 52 week13.96 Last close15.7 Last change-0.44%
RSI30.91 Average true range0.58 Beta1.22 Volume93.53 K
Simple moving average 20 days-1.95% Simple moving average 50 days-5.25% Simple moving average 200 days-22.9%
Performance Data
Performance Week0.96% Performance Month-4.85% Performance Quart-16.62% Performance Half-28.18%
Performance Year3.84% Performance Year-to-date-39.31% Volatility daily1.39% Volatility weekly3.11%
Volatility monthly6.37% Volatility yearly22.06% Relative Volume180.54% Average Volume143.47 K
New High New Low

News

2019-05-16 07:00:00 | Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

2019-05-14 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences

2019-05-07 13:51:01 | Why Concert Pharmaceuticals, Inc.'s NASDAQ:CNCE CEO Pay Matters To You

2019-05-02 17:39:28 | Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT

2019-05-02 11:52:23 | Concert Pharmaceuticals, Inc. CNCE Q1 2019 Earnings Call Transcript

2019-05-02 08:01:44 | Concert: 1Q Earnings Snapshot

2019-05-02 07:00:00 | Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-04-29 07:00:00 | Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors

2019-04-25 10:34:02 | Earnings Preview: Concert Pharmaceuticals CNCE Q1 Earnings Expected to Decline

2019-04-25 07:00:00 | Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019

2019-04-11 09:46:01 | Concert Pharma Initiates Early-Stage Schizophrenia Study

2019-04-11 07:00:00 | Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting

2019-04-10 06:30:00 | Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

2019-04-08 15:09:00 | Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling

2019-04-08 14:45:00 | Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding

2019-03-25 10:42:02 | New Strong Sell Stocks for March 25th

2019-03-12 08:13:12 | New Strong Sell Stocks for March 12th

2019-03-12 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference

2019-03-07 08:40:01 | Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

2019-03-06 07:00:00 | Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

2019-03-01 07:00:00 | Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

2019-03-01 06:40:22 | Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 10:49:19 | Concert Pharmaceuticals, Inc. CNCE Q4 2018 Earnings Conference Call Transcript

2019-02-28 07:00:00 | Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs

2019-02-21 07:00:00 | Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019

2019-02-13 07:36:35 | Concert Pharmaceuticals, Inc. NASDAQ:CNCE: Time For A Financial Health Check

2019-02-12 08:00:00 | Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-11 07:00:00 | Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

2019-02-05 14:25:56 | Mizuho's 9 Best Biotech Stocks to Buy for 2019

2019-01-24 07:00:00 | Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

2019-01-22 07:00:00 | Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

2019-01-02 08:55:43 | How Much Are Concert Pharmaceuticals, Inc. NASDAQ:CNCE Insiders Spending On Buying Shares?

2018-12-19 23:39:54 | Do Hedge Funds Love Concert Pharmaceuticals Inc CNCE?

2018-12-17 07:00:00 | Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia

2018-11-28 08:41:01 | Vertex's VRTX Triple Combo Cystic Fibrosis Studies Succeed

2018-11-26 11:36:28 | Should You Be Concerned About Concert Pharmaceuticals Inc’s NASDAQ:CNCE Historical Volatility?

2018-11-12 08:45:00 | Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-12 07:00:00 | Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata

2018-11-07 07:00:00 | Concert Pharmaceuticals to Participate at Upcoming Investor Conferences

2018-11-05 16:01:00 | Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine

2018-11-01 16:00:00 | Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT

2018-11-01 08:38:24 | Concert: 3Q Earnings Snapshot

2018-11-01 07:00:00 | Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update

2018-10-25 07:00:00 | Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018

2018-10-12 09:15:00 | Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International — What Drives Growth in Today's Competitive Landscape

2018-10-10 13:56:46 | What is Behind Concert Pharmaceuticals Inc’s NASDAQ:CNCE Superior ROE?

2018-09-26 07:00:00 | Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata

2018-08-29 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences

2018-08-09 06:35:06 | Inside Concert Pharma's new HQ in popular Lexington biotech campus

2018-08-07 08:30:00 | Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of Marin, Eclipse Resources, MKS Instruments, and Container Store — Fundamental Analysis, Key Performance Indications